Moteur de recherche d’entreprises européennes
Financement de l’UE (7 451 044 €) : L’inflammation chez l’homme au début de la vie : cibler les impacts sur la santé tout au long de la vie Hor29/11/2022 Programme de recherche et d'innovation de l'UE « Horizon »
Texte
L’inflammation chez l’homme au début de la vie : cibler les impacts sur la santé tout au long de la vie
The development of the human immune system in early life, including in utero, impacts the risks of several diseases later in life, particularly immune-mediated diseases such as allergies, asthma, and autoimmunity. Yet, the mechanisms of early life immune imprinting have been poorly understood in humans due to the difficulty in obtaining samples and the challenges of deriving the most important data from small sample volumes available. Furthermore, these studies are complicated by the many simultaneous exposures with potential impact on developing immune cells, colonising microbes, and immune-microbe mutualism. To better understand such interactions, a combinations of large population studies with longitudinal data and long-term follow-up and more detailed studies in smaller sets of children will be needed. Here we propose such a combined and interdisciplinary approach by intersecting multiple cohorts and existing biobanks, applying state-of the art technologies for exposure analyses and immune system investigation. This will enable us to understand the environmental factors shaping human immune systems early in life, their mechanisms of action, and impact on life-course health. The specific objectives of INITIALISE are: 1. to elucidate how exposures and genome impact gut microbiome, host immune system and metabolism, and how the interplay of these factors impact life-course health. 2. to define the role of the maturation of the immune system as a mediator between exposures and life-course health. Functional studies will be performed, to test specific mechanisms of environmental factors differing among children with different health outcomes and their imprinting on developing immune cells. 3. to perform a pilot clinical study, targeting the immune system, for personalised disease prevention. 4. to set up a collaborative data science platform for the studies of early-life factors linked with life-course health.
| The University Court of the University of Aberdeen | ? |
| ACADEMISCH ZIEKENHUIS GRONINGEN | 717 474 € |
| Agencia Estatal Consejo Superior de Investigaciones Cientificas | 339 038 € |
| EMPIRICA GESELLSCHAFT FUR KOMMUNIKATIONS UND TECHNOLOGIEFORSCHUNG mbH | 179 250 € |
| GENOS d.o.o. | 538 750 € |
| HELSINGIN YLIOPISTO | 699 666 € |
| Karolinska Institutet | 874 573 € |
| Linkopings Universitet | 399 353 € |
| Orebro University | 1 175 164 € |
| TURUN YLIOPISTO | 1 826 148 € |
| Universita Degli Studi Di Napoli Federico II | 505 725 € |
| UNIVERSITY OF FLORIDA | 195 905 € |
https://cordis.europa.eu/project/id/101094099
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel. L’état actuel est présenté à la page suivante : The University Court of the University of Aberdeen, Aberdeen, Royaume Uni.
